|Fastest Growing Market:||Asia Pacific|
|Largest Market:||North America|
Need a report that reflects how COVID-19 has impacted this market and its growth?
The peptide therapeutics market was valued at approximately USD 28,510.60 million in 2020, and it is expected to register a CAGR of 9.66% over the forecast period.
Novel peptides are being developed and repurposed as therapeutics for the treatment of COVID-19. Globally, researchers continue to search for compounds that either block the mechanisms important for SARS-CoV-2 infection and replication or treat conditions caused by the infection. On February 21, 2020, the FDA updated its definition of a biologic to include chemically synthesized polypeptides greater than 40 amino acids but less than 100 amino acids in size (synthetic proteins) and synthetic peptides 40 amino acids or less. As of May 2020, there were 21 peptide drugs for the treatment of COVID-19, including 15 synthetic peptides in development for the treatment of acute respiratory distress syndrome (ARDS) and other respiratory illnesses caused by SARS-Cov-2 infection. Hence, COVID-19 may have a positive impact on the peptide therapeutics market as peptide drugs are being considered as a treatment option for dealing with COVID-19. However, the current applications of peptide therapeutics in oncology, metabolic disorders, etc., have been disrupted due to a shortage of drugs and supply chain issues, along with the slow progress of clinical trials related to non-COVID-19 therapeutics.
The major factors driving the market growth are the increasing prevalence of cancer and metabolic disorders, rising investments in research and development of novel drugs, and technological advancements in peptide therapeutics. According to the World Health Organization (WHO), chronic diseases, such as cancer, cardiovascular diseases, and diabetes, are the leading causes of death and disability worldwide. Disease rates from chronic conditions are accelerating globally, advancing across every region and pervading all socioeconomic classes. In 2020, the contribution of chronic diseases was estimated to have caused 73% of all deaths and 60% of the global burden of diseases. Thus, the increasing incidence of chronic diseases accelerates the need for effective therapeutics, which in turn, is expected to drive the growth of the peptide therapeutics market. However, instability issues of peptide therapeutics, the high cost of developing drugs, and stringent regulatory requirements for drug approval are expected to restrain the market growth.
Scope of the Report
As per the scope of the report, peptides are short chains of amino acid monomers linked by peptide bonds. Peptides are distinguished from proteins on the basis of size, and as a benchmark, can be understood to contain approximately 50 amino acids or less. The peptide therapeutics market is segmented by marketing type, application, route of administration, and geography. By marketing type, the market is segmented into generic and branded. By application, the market is segmented into gastrointestinal disorders, neurological disorders, metabolic disorders, cancer, and other applications. By route of administration, the market is segmented into parenteral, oral, and other routes of administration. By geography, the market is segmented into North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers the value (USD million) for all the above segments.
|Route of Administration|
|Other Routes of Administration|
Key Market Trends
The Cancer Segment is Expected to Register the Highest CAGR Over the Forecast Period
Peptides offer favorable prospects in targeted drug delivery for cancer due to their high specificity, discernment, small sizes, ease of modification, and high biocompatibility. The increasing frequency of cancer globally and increasing prescription of peptide therapeutics for cancer treatment are the key factors responsible for the dominance of this segment.
According to the International Agency Research on Cancer- GLOBOCAN 2020 report, a total of 19,292,789 new cancer cases were diagnosed worldwide in 2020, with 9,958,133 deaths due to cancer. Also, the five-year prevalent cases of cancer were estimated to be 50,550,287 globally. The number of new cancer cases is expected to reach 28,887,940 by 2040 worldwide. Thus, the high prevalence of cancer cases globally is expected to play a vital role in the growth of the studied segment over the forecast period. Furthermore, rising awareness among patients and healthcare professionals regarding the adverse effects of chemotherapy and radiation therapy is a major factor for the growing focus on alternative therapeutics such as peptide-based drugs.
However, according to the research article published in Nature Cancer, 2020, the COVID-19 pandemic is expected to have disrupted the spectrum of cancer care, including delayed diagnoses, treatment, and halting clinical trials aimed at developing efficient therapeutics for cancer treatment, within which peptide therapeutics for cancer treatment is of no exception. Hence, the studied segment is predicted to be significantly impacted due to the pandemic.
To understand key trends, Download Sample Report
North America Dominates the Market, and It is Expected to do Same during the Forecast Period
North America is expected to dominate the overall market throughout the forecast period. The market growth is due to factors such as a rise in awareness levels relating to peptide therapeutic products, the increasing necessity for diagnostics in cancer and other diseases, and the growing biotechnology industry.
The increasing research and development expenditure by governments and key players is also expected to help peptide therapeutics sustain dominance over the coming years. A properly established biopharmaceutical and pharmaceutical industry in this region is a major factor responsible for growth. In the North American region, the United States holds the largest market share due to factors such as the increasing number of research programs in the medical industry and the growing number of diseases in the country, which is anticipated to stimulate the demand in this region. According to the estimates of the American Cancer Society, in 2020, an estimated 1.8 million new cancer cases were diagnosed, and 606,520 cancer deaths were reported in the United States. Owing to the increasing burden of cancer, the demand for peptide therapeutics is expected to grow. Hence, given the aforementioned factors, the peptide therapeutics market is expected to witness significant growth in North America over the forecast period.
However, according to the research article published in Applied Clinical Trials, in October 2020, the COVID-19 pandemic caused major disruptions to clinical trial execution in the United States, impacting key stakeholders across the healthcare industry. The sponsors, CROs, and other organizations that support drug development shifted to remote working environments, and an estimated 80% of non-COVID-19 trials were stopped or interrupted as a result of the COVID-19 pandemic. Hence, COVID-19 is expected to have a significant impact on the non-COVID-19 peptide therapeutics market in the region during the pandemic.
To understand geography trends, Download Sample Report
The peptide therapeutics market is moderately competitive and consists of several major players. Some of the companies currently dominating the market are Eli Lilly and Company, Pfizer Inc., Amgen Inc., Bristol-Myers Squibb Company, EVER NEURO PHARMA GmbH, Takeda Pharmaceutical Company Limited, and many others. The major players are involved in strategic alliances such as acquisitions and collaborations, along with research activities, for the global expansion of their product portfolios.
Bristol-Myers Squibb Company
Eli Lilly and Company
EVER NEURO PHARMA GMBH
- In September 2021, Nimble Therapeutics entered a strategic research collaboration with Incyte to include the discovery of additional novel peptide therapies.
- In May 2021, ISSAR Pharmaceuticals took the decision to license out its peptide-based new chemical entities (NCEs) with pre-IND filing and the United States Patent for various unmet healthcare needs of the population, making it affordable and accessible for better health outcomes.
Table of Contents
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Prevalence of Cancer and Metabolic Disorders
4.2.2 Rising Investments in Research and Development of Novel Drugs
4.2.3 Technological Advancements
4.3 Market Restraints
4.3.1 Instability of Peptides
4.3.2 High Cost of Developing Drugs and Stringent Regulatory Requirements for Drug Approval
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD Million)
5.1 Marketing Type
5.2.1 Gastrointestinal Disorders
5.2.2 Neurological Disorders
5.2.3 Metabolic Disorders
5.2.5 Other Applications
5.3 Route of Administration
5.3.3 Other Routes of Administration
5.4.1 North America
188.8.131.52 United States
184.108.40.206 United Kingdom
220.127.116.11 Rest of Europe
18.104.22.168 South Korea
22.214.171.124 Rest of Asia-Pacific
5.4.4 Middle-East and Africa
126.96.36.199 South Africa
188.8.131.52 Rest of Middle-East and Africa
5.4.5 South America
184.108.40.206 Rest of South America
6. COMPETITIVE LANDSCAPE
*List Not Exhaustive
6.1 Company Profiles
6.1.1 Eli Lilly and Company
6.1.2 Amgen Inc.
6.1.3 Pfizer Inc.
6.1.4 Bristol-Myers Squibb Company
6.1.5 Ever Neuro Pharma GmbH
6.1.6 Takeda Pharmaceutical Company Limited
6.1.7 Teva Pharmaceuticals Industries Ltd
6.1.8 AstraZeneca PLC
6.1.9 GlaxoSmithKline PLC
6.1.10 Novo Nordisk AS
6.1.11 Novartis AG
6.1.12 Zealand Pharma AG
6.1.13 AmbioPharm Inc.
6.1.14 Bachem Holding AG
6.1.15 PolyPeptide Group
6.1.16 Sanofi SA
6.1.17 Amylin Pharmaceuticals
6.1.18 CirclePharma Inc.
6.1.19 PeptiDream Inc.
6.1.20 Apitope Technology
6.1.21 Arch NioPartners
6.1.22 Galena Biopharmaceuticals
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
8. IMPACT OF COVID-19 ON THE MARKET
Frequently Asked Questions
What is the study period of this market?
The Peptide Therapeutics Market market is studied from 2019 - 2027.
What is the growth rate of Peptide Therapeutics Market?
The Peptide Therapeutics Market is growing at a CAGR of 9.66% over the next 5 years.
Which region has highest growth rate in Peptide Therapeutics Market?
Asia Pacific is growing at the highest CAGR over 2021- 2026.
Which region has largest share in Peptide Therapeutics Market?
North America holds highest share in 2021.
Who are the key players in Peptide Therapeutics Market?
Amgen, Inc., Pfizer, Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, EVER NEURO PHARMA GMBH are the major companies operating in Peptide Therapeutics Market.